Squadron Capital Management LLC
13F Reported Value
ⓘ$322.2M
incl. option notional
Equity Holdings
ⓘ$292.1M
Option Notional
ⓘ$30.2M
$0 puts / $30.2M calls
Holdings
43
Latest Filing
2026-06-30
Filing Quarter
Q2 2026
Portfolio Overview
Squadron Capital Management LLC disclosed 43 positions worth $322.2M in its Form 13F-HR for Q2 2026 — $292.1M in common stock plus $30.2M of put/call option positions (reported at underlying notional value, not premium at risk), led by $RLMD (RELMADA THERAPEUTICS, INC.) at 17.4% of the equity portfolio, followed by $CCCC and $COGT. During the quarter the fund opened 23 new positions and exited 17 — including a new stake in $ELVN and a full exit from $KALV. The portfolio is most concentrated in Healthcare (100.0% of disclosed assets). All figures are sourced directly from Squadron Capital Management LLC’s Form 13F-HR filing with the SEC under CIK 2050709.
AI Fund Analysis
StableSector Allocation
AUM History
Top Equity Holdings by Value
Option Positions
13F rules report options at the value of the underlying shares (notional) — not the premium paid or capital at risk. Shown separately from the equity sleeve above.
Quarterly Activity — Q2 2026
Click any card to unlockTop Holdings
- —
Quality
$50.9M7,350,000 sh - 18.2#2,812
Quality
$33.6M7,200,000 sh - —
Quality
$33.5M865,000 sh - —
Quality
$19.5M500,000 sh - 19.5
Quality
$18.1M970,000 sh - 11.6
Quality
$17.9M3,700,000 sh - —
Quality
$11.8M290,000 sh - 10.3
Quality
$10.0M335,000 sh - —
Quality
$9.2M2,435,000 sh - —
Quality
$8.8M764,876 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 RELMADA THERAPEUTICS, INC.$RLMD | — | $50.9M | 7,350,000 |
 C4 Therapeutics, Inc.$CCCC | 18.2#2,812 | $33.6M | 7,200,000 |
 Cogent Biosciences, Inc.$COGT | — | $33.5M | 865,000 |
 Kodiak Sciences Inc.$KOD | — | $19.5M | 500,000 |
 Relay Therapeutics, Inc.$RLAY | 19.5 | $18.1M | 970,000 |
 Zentalis Pharmaceuticals, Inc.$ZNTL | 11.6 | $17.9M | 3,700,000 |
 Edgewise Therapeutics, Inc.$EWTX | — | $11.8M | 290,000 |
 Maze Therapeutics, Inc.$MAZE | 10.3 | $10.0M | 335,000 |
 Inventiva S.A.$IVA | — | $9.2M | 2,435,000 |
 Adlai Nortye Group Ltd.$ANL | — | $8.8M | 764,876 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of Squadron Capital Management LLC's 43 positions.
Showing top 10 of 43 holdings.
Sector Allocation
Healthcare
$292.1M
Full Holdings — Squadron Capital Management LLC (Q2 2026)
All 43 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $RLMD | RELMADA THERAPEUTICS, INC. | $50.9M | 17.4% | -13% | — |
| 2 | $CCCC | C4 Therapeutics, Inc. | $33.6M | 11.5% | +220% | 18.2 |
| 3 | $COGT | Cogent Biosciences, Inc. | $33.5M | 11.5% | +10% | — |
| 4 | $KOD | Kodiak Sciences Inc. | $19.5M | 6.7% | +32% | — |
| 5 | $RLAY | Relay Therapeutics, Inc. | $18.1M | 6.2% | +44% | 19.5 |
| 6 | $ZNTL | Zentalis Pharmaceuticals, Inc. | $17.9M | 6.1% | +2% | 11.6 |
| 7 | $EWTX | Edgewise Therapeutics, Inc. | $11.8M | 4.0% | -17% | — |
| 8 | $MAZE | Maze Therapeutics, Inc. | $10.0M | 3.4% | +30% | 10.3 |
| 9 | $IVA | Inventiva S.A. | $9.2M | 3.1% | +355% | — |
| 10 | $ANL | Adlai Nortye Group Ltd. | $8.8M | 3.0% | -40% | — |
| 11 |  $ELVN | Enliven Therapeutics, Inc. | $8.1M | 2.8% | NEW | — |
| 12 |  $AVBPCALL | ArriVent BioPharma, Inc. | $6.4M | — | +66% | — |
| 13 |  $PALI | PALISADE BIO, INC. | $6.3M | 2.1% | +0% | — |
| 14 |  $BIOACALL | BioAge Labs, Inc. | $6.1M | — | NEW | 26.8 |
| 15 |  $IKT | Inhibikase Therapeutics, Inc. | $6.1M | 2.1% | -14% | — |
| 16 |  $ADAG | Adagene Inc. | $5.3M | 1.8% | NEW | — |
| 17 |  $FBRX | Forte Biosciences, Inc. | $4.8M | 1.6% | NEW | — |
| 18 |  $RZLTCALL | Rezolute, Inc. | $4.7M | — | NEW | — |
| 19 |  $IFRX | InflaRx N.V. | $4.5M | 1.5% | NEW | — |
| 20 |  $ASMB | ASSEMBLY BIOSCIENCES, INC. | $4.4M | 1.5% | NEW | 41.5 |
| 21 |  $CMPSCALL | COMPASS Pathways plc | $4.3M | — | NEW | — |
| 22 |  $PMN | ProMIS Neurosciences Inc. | $4.3M | 1.5% | +0% | — |
| 23 |  $CTNM | Contineum Therapeutics, Inc. | $4.3M | 1.5% | NEW | — |
| 24 | $CMPS | COMPASS Pathways plc | $4.2M | 1.4% | NEW | — |
| 25 |  $DFTX | Definium Therapeutics, Inc. | $4.0M | 1.4% | NEW | — |
| 26 |  $SLGL | Sol-Gel Technologies Ltd. | $3.9M | 1.3% | +68% | — |
| 27 | $BIOA | BioAge Labs, Inc. | $3.8M | 1.3% | NEW | 26.8 |
| 28 |  $SCYX | SCYNEXIS INC | $3.1M | 1.1% | -90% | — |
| 29 |  $PRQR | ProQR Therapeutics N.V. | $2.8M | 1.0% | NEW | — |
| 30 |  $IRONCALL | Disc Medicine, Inc. | $2.2M | — | NEW | — |
| 31 | $RZLT | Rezolute, Inc. | $2.1M | 0.7% | NEW | — |
| 32 |  $LPCN | Lipocine Inc. | $2.1M | 0.7% | +80% | — |
| 33 | $ZNTLCALL | Zentalis Pharmaceuticals, Inc. | $2.1M | — | +7% | 11.6 |
| 34 | $CCCCCALL | C4 Therapeutics, Inc. | $1.9M | — | NEW | 18.2 |
| 35 |  $RARECALL | Ultragenyx Pharmaceutical Inc. | $1.8M | — | NEW | 34.2 |
| 36 |  $CUE | Cue Biopharma, Inc. | $1.6M | 0.5% | NEW | 28.9 |
| 37 |  $CALC | CalciMedica, Inc. | $1.3M | 0.4% | NEW | — |
| 38 |  $QNCX | Quince Therapeutics, Inc. | $734,421 | 0.3% | NEW | — |
| 39 |  $NVCTCALL | Nuvectis Pharma, Inc. | $711,693 | — | NEW | — |
| 40 |  $KTTA | Pasithea Therapeutics Corp. | $515,400 | 0.2% | -52% | — |
| 41 |  $INM | InMed Pharmaceuticals Inc. | $503,750 | 0.2% | NEW | 13.1 |
| 42 |  $NMRA | Neumora Therapeutics, Inc. | $170,000 | 0.1% | NEW | — |
| 43 |  $NXTC | NextCure, Inc. | $103,142 | 0.0% | -76% | — |
New Positions (23)
$ELVN Enliven Therapeutics, Inc.$8.1M$BIOACALL BioAge Labs, Inc.$6.1M$ADAG Adagene Inc.$5.3M$FBRX Forte Biosciences, Inc.$4.8M$RZLTCALL Rezolute, Inc.$4.7M$IFRX InflaRx N.V.$4.5M$ASMB ASSEMBLY BIOSCIENCES, INC.$4.4M$CMPSCALL COMPASS Pathways plc$4.3M$CTNM Contineum Therapeutics, Inc.$4.3M$CMPS COMPASS Pathways plc$4.2M$DFTX Definium Therapeutics, Inc.$4.0M$BIOA BioAge Labs, Inc.$3.8M$PRQR ProQR Therapeutics N.V.$2.8M$IRONCALL Disc Medicine, Inc.$2.2M$RZLT Rezolute, Inc.$2.1MExited Positions (17)
$KALV KalVista Pharmaceuticals, Inc.
$ABVX Abivax S.A.
$NKTR NEKTAR THERAPEUTICS$KALVCALL KalVista Pharmaceuticals, Inc.
$EPRX EUPRAXIA PHARMACEUTICALS INC.
$GHRS GH Research PLC
$KPTIPUT Karyopharm Therapeutics Inc.
$IDYAPUT IDEAYA Biosciences, Inc.$IDYACALL IDEAYA Biosciences, Inc.
$ALXO ALX ONCOLOGY HOLDINGS INC
$CNTX Context Therapeutics Inc.$RLAYCALL Relay Therapeutics, Inc.
$TRAW Traws Pharma, Inc.
$TXMD TherapeuticsMD, Inc.
$SPRB SPRUCE BIOSCIENCES, INC.Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for Squadron Capital Management LLC including:
Track Squadron Capital Management LLC's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for Squadron Capital Management LLC and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: Squadron Capital Management LLC
13F Pro is an AI hedge fund tracker and stock research platform. For Squadron Capital Management LLC (SEC CIK: 2050709), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in Squadron Capital Management LLC's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.